LYME ANTIBODY SCREEN W/ REFLEX

LAB2726

59259

1 mL serum

0.5 mL

Transport tube

Room temperature

Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days

Gross hemolysis • Grossly lipemic

Mon-fri

1-4 days

Index	Interpretation
<0.90	Negative
0.90-1.09	Equivocal
>1.09	Positive

As recommended by the Food and Drug Administration (FDA), all samples with positive or equivocal results in a Borrelia burgdorferi antibody screen will be tested using a blot method. Positive or equivocal screening test results should not be interpreted as truly positive until verified as such using a supplemental assay (e.g., B. burgdorferi blot).
The screening test and/or blot for B. burgdorferi antibodies may be falsely negative in early stages of Lyme disease, including the period when erythema migrans is apparent.

Lyme disease is caused by a bacterium borrelia burgdorferi and is transmitted by ticks. EIA is the screening test with high sensitivity for antibody detection. Immunoblot testing qualitatively examines with high specificity antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected EIA test result.